Geisler J P, Wiemann M C, Miller G A, Zhou Z, Geisler H E
Department of Obstetrics and Gynecology, St. Vincent Hospital and Health Care Center, Indianapolis, IN 46260, USA.
J Surg Oncol. 1995 May;59(1):45-7. doi: 10.1002/jso.2930590112.
Malignant mixed mesodermal tumors of the ovary occur in less than 1% of cases of ovarian cancer. They have a dismal prognosis and the most effective type of therapy is still not known. All cases of malignant mixed mesodermal tumor of the ovary between January 1, 1985 and May 1, 1994 operated on by the gynecologic oncology service are the subject of this report. Data were obtained from the hospital and office records of the patients. Nine patients who had their primary surgery by the gynecologic oncology service were found to have the diagnosis of malignant mixed mesodermal tumor of the ovary. Homologous tumors were found in five patients and heterologous tumors in four. Homologous tumors (mean survival 15.2 months) showed a better survival than heterologous tumors (mean survival 6.5 months; P = 0.001). An elevated estrogen receptor status was shown to correspond to longer survival (P < 0.0001). Six specimens were considered to be estrogen receptor positive and three were receptor negative. The mean survival in those patients who had a positive estrogen receptor status, 13.7 months, with a median of 7.5 months was significantly higher than those who were not positive, 6.7 months (P = 0.019) with a median of 6.25 months. All specimens were progesterone receptor negative. Malignant mixed mesodermal tumors of the ovary have a dismal prognosis, no effective therapy, and controversial prognostic indicators. Increasing estrogen receptor status appeared to correlate with longer mean survival. Larger, multi-institutional studies need to be done to determine the overall significance of these findings.
卵巢恶性中胚叶混合瘤在卵巢癌病例中所占比例不到1%。其预后很差，最有效的治疗类型仍不明确。本报告的研究对象为1985年1月1日至1994年5月1日期间由妇科肿瘤服务部门进行手术的所有卵巢恶性中胚叶混合瘤病例。数据来自患者的医院和办公室记录。发现有9名接受妇科肿瘤服务部门初次手术的患者被诊断为卵巢恶性中胚叶混合瘤。其中5例为同源性肿瘤，4例为异源性肿瘤。同源性肿瘤（平均生存期15.2个月）的生存期比异源性肿瘤（平均生存期6.5个月；P = 0.001）更好。雌激素受体水平升高与更长的生存期相关（P < 0.0001）。6份标本被认为雌激素受体阳性，3份为受体阴性。雌激素受体阳性患者的平均生存期为13.7个月，中位数为7.5个月，显著高于雌激素受体阴性患者的6.7个月（P = 0.019），中位数为6.25个月。所有标本孕激素受体均为阴性。卵巢恶性中胚叶混合瘤预后很差，没有有效的治疗方法，预后指标也存在争议。雌激素受体水平升高似乎与更长的平均生存期相关。需要进行更大规模的多机构研究来确定这些发现的总体意义。
